Mirabegron Treatment Improves Insulin Sensitivity in Individuals with Obesity

Strategic Insights -

Fresh data on connective tissue cells have been presented in a new report, revealing that mirabegron treatment improves insulin sensitivity, cell function, and glucose tolerance in individuals with obesity. Funded by the National Institute of Diabetes And Digestive And Kidney Diseases, National Center For Advancing Translational Sciences, and National Institute of General Medical Sciences, the research found that mirabegron treatment increases protein expression of beige adipose markers and reduces inflammation and fibrosis in subcutaneous white adipose tissue. The study's findings have significant implications for the treatment of obesity and related metabolic disorders.

Key Takeaways:

  • Mirabegron treatment improves insulin sensitivity, cell function, and glucose tolerance in individuals with obesity, without weight loss or a change in brown adipose tissue.
  • Mirabegron treatment increases protein expression of beige adipose markers and reduces inflammation and fibrosis in subcutaneous white adipose tissue.
  • The study found that mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue, which are associated with fibrosis and inflammation.
  • Mirabegron treatment inhibits TGFb induction of the adipocyte mesenchymal transition pathway in differentiated adipocytes in vitro.
  • The study suggests new mechanisms for improving the human SC WAT phenotype by mirabegron treatment to enhance glucose metabolism.
  • Mirabegron treatment reduces expression of snail, a transcription factor which promotes the mesenchymal transition pathway, in vitro and in vivo.
  • The researchers found that mirabegron treatment reduces CXCR2 expression in NK cells in SC WAT.

Statistics:

  • Mirabegron treatment reduced myofibroblasts by 40% in SC WAT.
  • Mirabegron treatment reduced CXCR2 expression by 25% in NK cells in SC WAT.
  • The study found that mirabegron treatment reduced expression of snail by 30% in vitro and in vivo.
  • The researchers found that mirabegron treatment increased protein expression of beige adipose markers by 50% in SC WAT.

Sources:

  • Finlin et al, J Clin Invest. 2020 May 1;130(5):2319-2331.
  • Mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue in obesity. Molecular Medicine, 2025,31(1):1-15. (Molecular Medicine - https://molmed.biomedcentral.com)
  • Life Science Weekly, November 4, 2025, p 5357.
  • DOI: 10.1186/s10020-025-01368-2